
    
      This project is a double-blinded randomized Phase I study that will include dose-ranging one
      day PK and pharmacodynamic (PD) studies. Subjects will include healthy individuals and
      subjects who meet the American Diabetes Association (ADA) criteria for pre-diabetes,
      including IFG.
    
  